- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
http://www.docguide.com/adding-bicyclol-adefovir-dipivoxil-provides-clinical-benefit-patients-chronic-hbv?hash=c8431e6c&eid=19247&alrhash=2f4244-e14fac0ff7ef1d5b0c78458126191858
Adding Bicyclol to Adefovir Dipivoxil Provides Clinical Benefit to Patients With Chronic HBV
By Chris Berrie
BERLIN -- April 4, 2011 -- Addition of bicyclol to adefovir dipivoxil (ADV) is safe and effective for patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B virus (HBV), according to a study presented here at the 46th Annual Meeting of the European Association of the Study of the Liver (EASL).
Bicyclol is a new antihepatitis drug with antioxidative and anti-inflammation properties that has shown liver protective effects for patients with viral hepatitis, drug-induced liver injury, alcohol liver diseases, and autoimmune liver diseases.
“Inflammation is still a problem, particularly as inflammation for AST [aspartate aminotransferase] levels is correlated to the outcome for cirrhosis, hepatocellular carcinoma, and decompensated liver diseases,” said Jun Cheng, MD, Beijing Ditan Hospital, Capital Medical University, Beijing, China, on April 1. “So, if we use the antiviral plus anti-inflammation, maybe we can increase the efficacy of the therapy.”
The study included 250 patients who were randomised to oral ADV 10 mg daily without (n = 125) or with (n = 125) oral bicyclol 25 mg TID, for 48 weeks.
Liver biopsies were taken at baseline and at 48 weeks in 87 of the patients (45 patients in the combination group), for evaluation of liver histology activity index, necroinflammation, and fibrosis. The mean Knodell scores at baseline were 7.0 and 7.4, respectively.
There were no significant differences between groups for HBV DNA levels at week 48 (3.1 vs 3.3 log10 copies/mL for combination).
However, at 48 weeks, significantly lower levels of alanine aminotransferase (30.3 vs 46.4 U/L; P <.01) and AST (67.9 vs 46.6 U/mL; P <.01) were seen for patients receiving bicyclol versus those receiving ADV alone.
In addition, Knodell necroinflammatory scores were significantly improved in patients receiving bicyclol versus ADV alone (P <.05).
There were no remarkable adverse events seen that might have been related to bicyclol addition to ADV.
“The key point from these results is the Knodell scores,” said Dr. Cheng. “We get a better improvement in the histology, so it is worth doing the combination therapy using the antiviral plus the anti-inflammation.”
Funding for this study was provided by Beijing Union Pharmaceutical Factory.
[Presentation title: A Randomized, Multi-Central, Controlled Study of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B Treated by Adefovir Dipivoxil or Adefovir Dipivoxil Plus Bicyclol. Abstract 709]
|
-
总评分: 现金 + 18
查看全部评分
|